Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1082)	12/9/1998 4:28:00 PM
From: Rob L.	Read Replies (1) \| Respond to of 1580

Those numbers suggest Merck is grossly overvalued. At $4.95 the PE is around 32 and the earnings growth is only 14%. Either price has to come down or earnings have to go up. CEO says earnings estimates are reasonable which means MRK will probabably beat them, but not by enough to bring the stock down to earth. The only chance this stock has is if the blockbuster drugs develop into something unexpected. Those that put a buy out on this company at these prices are misleading investors IMO. I might consider taking some profits after digesting all of this news.